Kallikrein-3 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Kallikrein-3 (PSA, KLK3; UniProt P07288), expressed in HEK293 cells. Suited for semenogelin cleavage assays, serine protease inhibitor screens, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Kallikrein3

In stock

SKU
REC-Kallikrein3
$498.00

Target Overview

Kallikrein-3 (KLK3), more commonly known as prostate-specific antigen (PSA), is a secreted serine protease of the kallikrein-related peptidase family encoded by the KLK3 gene on chromosome 19q13.4. The full-length precursor spans 261 amino acids (UniProt P07288) and is processed to its mature, enzymatically active form following cleavage of a 17-residue signal peptide and a 7-residue propeptide activation segment. Its catalogued EC number is 3.4.21.77, placing it among the chymotrypsin-like serine endopeptidases. This recombinant is produced in HEK293 mammalian cells, providing glycosylation and folding conditions appropriate for a secreted human protease. Mammalian-cell expression is generally preferred for Kallikrein-3 over bacterial systems because correct disulfide bond formation and N-linked glycosylation are required for full enzymatic activity and proper antigenic presentation. In vitro, Kallikrein-3 cleaves semenogelin-1 and semenogelin-2, the principal structural proteins of the seminal coagulum; this activity can be measured directly using peptide or protein substrates in fluorometric cleavage assays. The recombinant protein is also used as a positive control antigen in Western blot and ELISA development, and as a competition standard in calibration experiments. Because KLK3 protein levels are a widely used quantitative biomarker in prostate biology research, purified recombinant antigen with defined concentration and purity is critical for assay standardisation. Researchers building or validating immunoassays for KLK3 can pair this recombinant directly with the matched Triple Point Biologics antibody (SKU: RP-Kallikrein3), which has been validated for Western blot against human KLK3, with predicted cross-reactivity to non-human primate and Pan species.

Background

Kallikrein-3 (KLK3/PSA) is a member of the 15-gene human tissue kallikrein family and represents one of the most extensively studied serine proteases in biomedical research. It is produced almost exclusively in the luminal epithelial cells of the prostate gland, where it is secreted into seminal plasma at millimolar concentrations. Its primary physiological substrate is semenogelin-1, whose proteolytic degradation results in liquefaction of the seminal coagulum — a process essential for normal reproductive biology in humans. Circulating forms of KLK3 in blood exist in both free and complexed states (principally bound to alpha-1-antichymotrypsin and alpha-2-macroglobulin), a distinction that has driven substantial research into the structural determinants of inhibitor binding and the relative immunoreactivity of each molecular form. From a basic research perspective, KLK3 has been investigated as a quantitative tissue and circulating biomarker for prostate epithelial mass and function. A 2026 post-hoc analysis of five phase 3 STAMPEDE trials (Kayani et al., Lancet Oncol.) examined on-treatment serum KLK3 levels in relation to survival outcomes in prostate cancer patients, underscoring the sustained research interest in how KLK3 dynamics reflect disease biology. Separately, plasma proteomic studies such as the large-scale prospective cohort work by Li et al. (J Glob Health, 2026) have identified KLK3 among proteomic signatures associated with benign prostatic hyperplasia incidence, illustrating its utility as a quantifiable protein analyte in population-level omics research. At the molecular level, KLK3 has been studied as a research target in the context of androgen receptor signalling, given that its promoter contains functional androgen response elements and its expression is tightly regulated by androgen receptor activity. This makes it a useful transcriptional reporter in cell-based models of androgen pathway biology. Network toxicology and molecular docking studies (Du A et al., Oncol Res, 2026) have also characterised KLK3 as a computational interaction node in mechanistic analyses of environmental exposures and prostate epithelial biology. Recombinant KLK3 produced in mammalian expression systems serves the research community as: a well-defined enzyme source for serine protease inhibitor profiling; a calibration standard for quantitative immunoassays; a positive-control antigen for antibody lot validation; and a structural substrate for biophysical characterisation of protease–inhibitor complexes. Triple Point Biologics has produced proteinase and inhibitor reagents since 1994, and this HEK293-expressed recombinant is manufactured to support reproducible in vitro research applications.

Applications

  • Semenogelin-1 cleavage activity assay using fluorogenic peptide substrates
  • Serine protease inhibitor IC50 determination (e.g., against alpha-1-antichymotrypsin analogues)
  • Western blot positive-control antigen for anti-KLK3 antibody validation (pairs with SKU RP-Kallikrein3)
  • IHC standard preparation and antigen spike recovery for tissue lysate experiments
  • Quantitative ELISA calibration standard for free or total PSA immunoassay development
  • Substrate-based kinetic characterisation (Km, kcat) of KLK3 chymotrypsin-like activity
  • Molecular docking and biophysical binding studies with candidate small-molecule inhibitors
  • Androgen receptor pathway reporter validation — recombinant antigen for confirming KLK3 secretion in cell supernatants

References

  1. Kayani M et al. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials. Lancet Oncol. 2026. doi:10.1016/S1470-2045(26)00066-5 PMID: 42061373
  2. Li H et al. Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men. J Glob Health. 2026. doi:10.7189/jogh.16.04185 PMID: 42281484
  3. Suzuki T et al. Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. Int J Urol. 2026. doi:10.1111/iju.70533 PMID: 42226505
  4. Du J et al. Multi-omics integration predicts the incidence of 17 diseases in the UK Biobank. Nat Commun. 2026. doi:10.1038/s41467-026-73017-z PMID: 42106324
  5. Du A et al. Elucidating the Potential Targets and Mechanisms of Bisphenol A-Induced Prostate Cancer Based on Network Toxicology and Molecular Docking Analyses. Oncol Res. 2026. doi:10.32604/or.2026.076716 PMID: 42065064

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma; tissue

Frequently Asked Questions

What molecular weight band should I expect for recombinant Kallikrein-3 on SDS-PAGE or Western blot?

The mature, enzymatically active form of Kallikrein-3 (after removal of the 17-residue signal peptide and 7-residue propeptide) has a predicted polypeptide MW of approximately 26 kDa. Because this recombinant is produced in HEK293 cells with native-like N-linked glycosylation, the apparent MW on reducing SDS-PAGE typically runs at 28–33 kDa — a diffuse band is normal and reflects heterogeneous glycosylation. Under non-reducing conditions, the band may shift slightly due to intramolecular disulfide constraints. If you observe a doublet, this is consistent with partially processed pro-forms co-purifying with the mature enzyme.

Is this recombinant PSA the proenzyme form or the mature enzymatically active form of Kallikrein-3?

This product is supplied as the mature, active form of Kallikrein-3 (EC 3.4.21.77), corresponding to residues 25–261 of UniProt P07288 after cleavage of both the signal peptide (residues 1–17) and the activation propeptide (residues 18–24). It is not the zymogen (pro-PSA). Enzymatic activity is confirmed prior to lot release. If your experiment specifically requires the proPSA isoform — relevant in certain cancer biomarker contexts — note that this product will not model the uncleaved precursor state.

What substrates does recombinant Kallikrein-3 cleave, and what synthetic substrate can I use in an activity assay?

Kallikrein-3 is a chymotrypsin-like serine endopeptidase that cleaves semenogelin-1 and semenogelin-2 at specific Tyr and Leu residues in its physiological context. For in vitro activity assays, the fluorogenic substrate H-Ser-Ser-Lys-Leu-Gln-AMC (or the commercially available Boc-Gln-Ala-Arg-AMC as a secondary option) is commonly used and well-documented in the literature. Cleavage is measured by AMC release at excitation 360 nm / emission 460 nm. Confirm activity is zinc-independent (Kallikrein-3 is a serine protease, not a metalloprotease), so avoid including EDTA in your assay buffer above 0.1 mM.

What buffer conditions should I use for a Kallikrein-3 enzymatic activity assay, and what is the recommended starting enzyme concentration?

For activity assays, a working buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl with 0.01% Tween-20 to prevent surface adsorption is a practical starting point — this is compatible with the storage buffer this protein ships in. A starting enzyme concentration of 1–5 nM is appropriate for fluorogenic substrate assays at substrate concentrations spanning the expected Km (typically 50–500 µM for AMC-conjugated peptides). Pre-incubate the enzyme at 37°C for 10 minutes before initiating the reaction. For IC50 determination of serine protease inhibitors, titrate enzyme at 2 nM to maintain linear substrate turnover throughout the inhibitor concentration range.

Can I use recombinant Kallikrein-3 as a positive control for Western blot with the matched rabbit polyclonal antibody RP-Kallikrein3?

Yes — this is a validated application. The matched rabbit polyclonal antibody (SKU: RP-Kallikrein3, available at /anti-kallikrein-3-rabbit-polyclonal-antibody) is produced and validated in the same laboratory against the mature Kallikrein-3 protein, making REC-Kallikrein3 the natural positive control for any Western blot run with RP-Kallikrein3. Both the antigen used for immunization and this recombinant are HEK293-expressed, so epitope conformation is matched. Expect a band at 28–33 kDa (glycosylated) with no ambiguity about which band is Kallikrein-3 when loaded alongside your cell lysate or tissue samples.

How much recombinant Kallikrein-3 should I load per lane as a Western blot positive control?

Load 50–200 ng of REC-Kallikrein3 per lane for standard Western blot with RP-Kallikrein3 antibody. At 50 ng, a clean single band at 28–33 kDa is detectable with chemiluminescent detection (ECL) at typical antibody dilutions (1:1,000–1:5,000). If your secondary antibody or detection system is less sensitive, scale up to 100–200 ng. Avoid loading more than 500 ng, as overloading a glycoprotein of this MW range tends to produce smearing that obscures the band relative to your lysate lanes. Run in a dedicated lane adjacent to your experimental samples rather than mixing into a single lane.

How should I handle, dilute, and store recombinant Kallikrein-3 to preserve enzymatic activity over time?

REC-Kallikrein3 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and stored at −20°C in single-use aliquots. Purity is >95% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL assay. Avoid repeated freeze-thaw cycles — activity loss per cycle is measurable for serine proteases of this class. For working dilutions, use the storage buffer or your assay buffer supplemented with 0.1% BSA as a carrier to prevent adsorption at low concentrations (<10 nM). Diluted enzyme should be prepared fresh on the day of the experiment and kept on ice. Do not store working dilutions at 4°C for more than 24 hours.

Does recombinant Kallikrein-3 from HEK293 cells have full enzymatic activity compared to E. coli-expressed PSA?

HEK293 expression is specifically preferred for Kallikrein-3 because the protein requires correct disulfide bond formation across its three conserved disulfide bridges and N-linked glycosylation for full enzymatic activity and proper antigenic presentation — neither of which is reliably achieved in bacterial systems without refolding. E. coli-expressed Kallikrein-3 typically requires denaturation and refolding steps that result in variable specific activity and altered glycan profiles. This recombinant is assayed for chymotrypsin-like serine protease activity prior to lot release, and the specific activity is reported on the lot-specific certificate of analysis provided with each shipment.

Validation imagery coming soon

Western blot validation figures for REC-Kallikrein3 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →